Research programme: small activating RNA therapeutics - MiNA TherapeuticsAlternative Names: RNAa - Mina Therapeutics; saRNA - MiNA Therapeutics
Latest Information Update: 06 Nov 2015
At a glance
- Originator MiNA Therapeutics; University of California at San Francisco; University of Texas Southwestern Medical Center
- Developer Marina Biotech; MiNA Therapeutics
- Class RNA
- Mechanism of Action RNA stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer